NAUT News and Press, Nautilus Biotechnology Inc. From 01/27/22

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the fourth quarter an...

Nautilus Biotechnology (NAUT +9.1%) director Perceptive Advisors purchased 200,000 shares at ~$5.36 on December 8, transaction value $1.1M. This brings the total holding to 9.1M shares. Form 4 The stock jumped on December as Sujal M Patel, CEO, President bought 2.5M shares. The stock has a ma...

Penny stocks have become some of the hottest things to buy during this latest leg of the market’s bull run. Despite the pullback in the S&P 500 this week, the slight dip pales in comparison to the year-to-date move so far. This year, for example, the SPY ETF started January a...

Following a decline of ~8.3% on Wednesday, the shares of Nautilus Biotechnology (NAUT +7.4%) have rebound after the CEO of the life sciences company, Sujal Patel, disclosed the purchase of 250K company shares. According to an SEC filing on Thursday, Patel has executed the transaction early th...

Nautilus Biotechnology, Inc. (NAUT) Q3 2021 Earnings Conference Call November 2, 2021 08:30 ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientific Officer Anna Mowry - Chief Financial Officer Conference Call Participant...

Cowen has initiated Nautilus Biotechnology (NAUT +10.5%) with an outperform rating citing the company's early success in "unlocking" the proteome which could help in development of treatments for diseases. The firm does not have a price target on shares. Analyst Max Masucci says that the risk...

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome As an element of Nautilus' overall reagent development and sourcing strategy, the partnership aims to accelerate research and development, and provide customers with access to Abcam's ant...

Nautilus Biotechnology (NASDAQ:NAUT): Q3 GAAP EPS of -$0.12. Cash, cash equivalents, and investments were $374.0M as of September 30, 2021. For further details see: Nautilus Biotechnology reports Q3 results

SEATTLE, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial results for the third quarter ended September 30,...

The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....